Asset Publisher

ph-0235

print Print

Colony Stimulating Factors: Filgrastim (Neupogen®); Filgrastim-aafi (Nivestym™); Filgrastim-sndz (Zarxio™); Filgrastim-ayow (Releuko®); Tbo-Filgrastim (Granix®)

Policy Number: PH-0235

 

Subcutaneous/Intravenous

 

Last Review Date: 03/31/2023

Date of Origin: 10/17/2008

Dates Reviewed: 06/2009, 12/2009, 06/2010, 07/2010, 09/2010, 12/2010, 03/2011, 6/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 04/2019, 04/2020, 04/2021, 04/2022, 07/2022, 04/2023

FOR PEEHIP Members Only -Coverage excludes the provider-administered medication(s) outlined in this drug policy from being accessed through a specialty pharmacy. It must be obtained through buy and bill.

  1. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

  1. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

  • Neupogen 300 mcg single-dose vial: 3 vials per 1 day
  • Neupogen 300 mcg single-dose prefilled syringe (SingleJect): 3 syringes per 1 day
  • Neupogen 480 mcg single-dose vial: 3 vials per 1 day
  • Neupogen 480 mcg single-dose prefilled syringe (SingleJect): 3 syringes per 1 day
  • Nivestym 300 mcg single-dose vial: 3 vials per 1 day
  • Nivestym 300 mcg single-dose prefilled syringe: 3 syringes per 1 day
  • Nivestym 480 mcg single-dose vial: 3 vials per 1 day
  • Nivestym 480 mcg single-dose prefilled syringe: 3 syringes per 1 day
  • Zarxio 300 mcg single-dose prefilled syringe: 3 syringes per 1 day
  • Zarxio 480 mcg single-dose prefilled syringe: 3 syringes per 1 day
  • Releuko 300 mcg single-dose prefilled syringe: 3 syringes per 1 day
  • Releuko 480 mcg single-dose prefilled syringe: 3 syringes per 1 day
  • Releuko 300 mcg single-dose vial: 3 vials per 1 day
  • Releuko 480 mcg single-dose vial: 3 vials per day
  • Granix 300 mcg single-dose pre-filled syringe: 4 syringes per 1 day
  • Granix 300 mcg single-dose vial: 4 vials per 1 day
  • Granix 480 mcg single-dose pre-filled syringe: 3 syringes per 1 day
  • Granix 480 mcg single-dose vial: 3 vials per 1 day

B. Max Units (per dose and over time) [HCPCS Unit]:

     Severe Chronic Neutropenia (Congenital Neutropenia):

  • 1380 billable units per day

      BMT or PBPC or H-ARS:

  • 1200 billable units per day

     All other indications:

  • 600 billable units per day
  1. Initial Approval Criteria

Coverage is provided in the following conditions:      

The patient has another FDA labeled or guideline supported (at highest level of evidence) indication.

  • For PEEHIP Members ONLY:
  • Patient must have tried and had an inadequate response or intolerance to, or a contraindication to Zarxio prior to consideration of another short-acting gCSF; AND
  • For Commercial Members ONLY:
  • Patient must have tried and had an inadequate response or intolerance to, or a contraindication to Nivestym AND Zarxio prior to consideration of another short-acting gCSF; AND

Bone Marrow Transplant (BMT) † ‡ Ф 1-6

Peripheral Blood Progenitor Cell (PBPC) mobilization and transplant † ‡ Ф 1-6,19,30,33,35-37

Prophylactic use in patients with solid tumors or non-myeloid malignancy † ‡ 1-7,9,10,12,13,15,17,27-29

  • Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of greater than 20% §; OR
  • Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of 10% to 20% § AND one or more of the following co-morbidities:
  • Age >65 years receiving full dose intensity chemotherapy
  • Extensive prior exposure to chemotherapy
  • Previous exposure of pelvis, or other areas of large amounts of bone marrow, to radiation
  • Pre-existing neutropenia (ANC ≤ 1000/mm3)
  • Bone marrow involvement with tumor
  • Patient has a condition that can potentially increase the risk of serious infection (i.e., HIV/AIDS with low CD4 counts)
  • Recent surgery and/or open wounds
  • Poor performance status
  • Renal dysfunction (creatinine clearance <50 mL/min)
  • Liver dysfunction (elevated bilirubin >2.0 mg/dL)
  • Chronic immunosuppression in the post-transplant setting including organ transplant

Note: Dose-dense therapy, in general, requires growth factor support to maintain dose intensity and schedule. In the palliative setting, consideration should be given to dose reduction or change in regimen.

Treatment of chemotherapy-induced febrile neutropenia ‡ 1-7,9,10,12,13,15,17,27-29

  • Patient has been on prophylactic therapy with filgrastim or tbo-filgrastim (Note: therapy should not be used concomitantly with pegfilgrastim); OR
  • Patient has not received prophylactic therapy with a granulocyte colony stimulating factor; AND
            • Patient has one or more of the following risk factors for developing infection-related complications:
      • Sepsis Syndrome
      • Age greater than 65 years
      • Absolute neutrophil count [ANC] less than 100/mcL
      • Duration of neutropenia expected to be greater than 10 days
      • Pneumonia or other clinically documented infections
      • Invasive fungal infection
      • Hospitalization at the time of fever
      • Prior episode of febrile neutropenia

Patient who experienced a neutropenic complication from a prior cycle of the same chemotherapy ‡ 1-7,9,10,12,13,15,17,27-29

Note: Dose-dense therapy, in general, requires growth factor support to maintain dose intensity and schedule. In the palliative setting, consideration should be given to dose reduction or change in regimen.

Acute Myeloid Leukemia (AML) † ‡ Ф 1-6,8,14,35

  • Used in patients receiving induction/consolidation or re-induction chemotherapy; OR
  • Used for relapsed or refractory disease

Bone Marrow Transplantation (BMT) failure or Engraftment Delay † ‡ 1-7,25,26,30,33,35-37

Severe Chronic Neutropenia † ‡ Ф 1-6,11

  • Patient must have an absolute neutrophil count (ANC) < 500/mm3; AND
  • Patient must have a diagnosis of one of the following:
    • Congenital neutropenia; OR
    • Cyclic neutropenia; OR
    • Idiopathic neutropenia

Myelodysplastic Syndrome ‡ 6

  • Patient has symptomatic anemia with no del(5q) mutation; AND
  • Patient has lower risk disease (i.e., defined as IPSS-R [Very Low, Low, Intermediate]); AND
  • Endogenous serum erythropoietin level of ≤500 mUnits/mL; AND
    • Patient has ring sideroblasts ≥15% (or ring sideroblasts ≥5% with an SF3B1 mutation); AND
      • Used in combination with an Erythropoiesis Stimulating Agent (ESA); OR
    • Patient has ring sideroblasts <15% (or ring sideroblasts <5% with an SF3B1 mutation); AND
      • Used in combination with an ESA following no response (despite adequate iron stores) or erythroid response followed by loss of response to ESA alone

Patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]) † ‡ Ф 1-6,18

Management of CAR T-cell related Toxicity 6

  • Patient has been receiving therapy with CAR T-cell therapy (e.g., axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel, etc.); AND
  • Patient is experiencing neutropenia related to their therapy

Wilms Tumor (Nephroblastoma) 6

  • Patient has favorable histology disease; AND
  • Used in combination with a cyclophosphamide-based chemotherapy regimen (i.e., Regimen M or I only)

FDA-labeled indication(s); Compendia recommended indication(s); Ф Orphan Drug

§Febrile neutropenia is defined as: 7

  • Temperature: a single temperature ≥38.3 °C orally or ≥38.0 °C over 1 hour; AND
  • Neutropenia: <500 neutrophils/mcL or <1,000 neutrophils/mcL and a predicted decline to ≤500 neutrophils/mcL over the next 48 hours

§ Expected incidence of febrile neutropenia percentages for myelosuppressive chemotherapy regimens can be found in the NCCN Hematopoietic Growth Factors Clinical Practice Guideline at NCCN.org 7

  1. Renewal Criteria

Coverage may be renewed based upon the following criteria:

  • Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; AND
  • Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: splenic rupture, acute respiratory distress syndrome (ARDS), serious allergic reactions/anaphylaxis, sickle cell crisis, glomerulonephritis, leukocytosis, capillary leak syndrome, potential for tumor growth stimulation of malignant cells, aortitis, alveolar hemorrhage and hemoptysis, thrombocytopenia, cutaneous vasculitis, MDS/AML (when used for congenital neutropenia), etc.
  1. Dosage/Administration 1-5

Indication

Dose

BMT/PBPC/H-ARS

10 mcg/kg daily for up to 14 days

Congenital Neutropenia

6 mcg/kg twice daily

All other indications

5 mcg/kg daily for up to 14 days

  1. Billing Code/Availability Information

HCPCS Code:

  • J1442 – Injection, filgrastim (g-csf), excludes biosimilars, 1 mcg: 1 billable unit = 1 mcg
  • Q5110 – Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 mcg: 1 billable unit = 1 mcg
  • Q5101 – Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg: 1 billable unit = 1 mcg
  • J1447 – Injection, tbo-filgrastim (Granix), 1 mcg: 1 billable unit = 1 mcg
  • Q5125 – Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg; 1 billable unit = 1 mcg

NDC:

  • Neupogen 300 mcg single-dose vial: 55513-0530-xx
  • Neupogen 300 mcg single-dose prefilled syringe (SingleJect): 55513-0924-xx
  • Neupogen 480 mcg single-dose vial: 55513-0546-xx
  • Neupogen 480 mcg single-dose prefilled syringe (SingleJect): 55513-0209-xx
  • Nivestym 300 mcg single-dose vial: 00069-0293-xx
  • Nivestym 300 mcg single-dose prefilled syringe: 00069-0291-xx
  • Nivestym 480 mcg single-dose vial: 00069-0294-xx
  • Nivestym 480 mcg single-dose prefilled syringe: 00069-0292-xx
  • Zarxio 300 mcg single-dose prefilled syringe: 61314-0318-xx
  • Zarxio 480 mcg single-dose prefilled syringe: 61314-0326-xx
  • Releuko 300 mcg single-dose prefilled syringe: 70121-1568-xx
  • Releuko 480 mcg single-dose prefilled syringe: 70121-1570-xx
  • Releuko 300 mcg single-dose vial: 70121-1569-xx
  • Releuko 480 mcg single-dose vial: 70121-1571-xx
  • Granix 300 mcg single-dose prefilled syringe: 63459-0910-xx
  • Granix 480 mcg single-dose prefilled syringe: 63459-0912-xx
  • Granix 300 mcg single-dose vial: 63459-0918-xx
  • Granix 480 mcg single-dose vial: 63459-0920-xx
  1. References
  1. Neupogen [package insert]. Thousand Oaks, CA; Amgen Inc; February 2021. Accessed March 2023.
  2. Nivestym [package insert]. Lake Forest, IL; Hospira Inc; March 2023. Accessed March 2023.
  3. Zarxio [package insert]. Princeton, NJ; Sandoz Inc; November 2022. Accessed March 2023.
  1. Releuko [package insert]. Piscataway, NJ; Kashiv Biosciences, Inc; April 2022. Accessed March 2023.
  2. Granix [package insert]. North Wales, PA; Teva Pharmaceuticals USA, Inc.; November 2019. Accessed March 2023.
  3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) filgrastim. National Comprehensive Cancer Network, 2023.  The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org.  Accessed March 2023.
  4. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hematopoietic Growth Factors. Version 2.2023.  National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org.  Accessed March 2023.
  5. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood. 1997;90:4710-4718.
  6. Rusthoven J, Bramwell V, Stephenson B. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Cancer Prev Control. 1998;2(4):179-190.
  7. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer. 2002;10(3):181-188.
  8. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81(10):2496-2502.
  9. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized Phase III study. J Clin Oncol. 2005;23:7974–84. doi: 10.1200/JCO.2004.00.7955.
  10. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–70.
  11. Lilienfeld-Toal M, Hahn-Ast C, Kirchner H, et al. A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy. Haematologica. 2007;92:1719–1720.
  12. García-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst. 2001;93(1):31-38.
  13. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90(12):4710-4718.
  14. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488.
  15. Farese AM, MacVittie TJ. Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs Today (Barc) 2015;51:537-48.
  16. Schmitt M, Publicover A, Orchard KH, et al. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Theranostics. 2014;4(3):280-289.
  17. Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf. 2013;12(2):235-246.
  18. Yao HM, Ottery FD, Borema T, et al. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. BioDrugs. 2019 Apr;33(2):207-220.
  19. Lubenau H, Sveikata A, Gumbrevicius G, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47(4):275-282.
  20. Gascon P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010 Jul;21(7):1419-29.
  21. Kelaidi C Beyne-Rauzy O, Braun T, et al. High Response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013; 92:621-631.
  22. Elayan MM, Horowitz JG, Magraner JM, et al. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024.
  23. Trifilio S, Zhou Z, Galvin J, et al. Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Clin Transplant. 2015 Oct 22. doi: 10.1111/ctr.12637.
  24. del Giglio A, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332.
  25. Gatzemeier U, Ciuleanu T, Dediu M, et al. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009;4(6):736-40.
  26. Engert A, Griskevicius L, Zyuzgin Y, et al. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009;50(3):374-79.
  27. Bhamidipati PK, Fiala MA, Grossman BJ, et al. Results of a prospective randomized, open-label, noninferiority study of tbo-filgrastim (Granix) versus filgrastim (Neupogen) in combination with Plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. August 7, 2017
  28. Engert A, del Giglio A, Bias P, et al. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: A meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie. 2009;32(10):599-604.
  29. Lubenau H, Bias P, Maly AK, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: Single-blind, randomized, crossover trial. BioDrugs. 2009;23(1):43-51.
  30. Andreola G, Babic A, Rabascio C, et al. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. Eur J Haematol. 2012;88(2):154-158.
  31. Bagalagel A, Mohammed A, MacDonald K, Abraham I. Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor. Biosimilars. 2013;2013(3):55-62.
  32. Danylesko I, Sareli R, Bloom-Varda N, et al. The use of Tevagrastim (biosimilar filgrastim XMO2) for hematopoietic stem cell mobilization In HLA matched sibling donors for allogeneic stem cell transplantation to AML/MDS patients. Blood. 2013;122(21):3275.
  33. Schmitt M, Xu X, Hilgendorf I, et al. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplant. 2013;48(7):922-925
  34. Schmitt M, Hoffmann JM, Lorenz K, et al. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Vox Sang. 2016;111(2):178-186.
  35. First Coast Service Options, Inc. Local Coverage Article: Billing and Coding: G-CSF Filgrastim (A57789). Centers for Medicare & Medicaid Services, Inc. Updated on 09/30/2022 with effective date 10/01/2022. Accessed March 2023.
  36. Palmetto GBA. Local Coverage Determination: White Cell Colony Stimulating Factors (A56748). Centers for Medicare & Medicaid Services, Inc. Updated on 12/13/2022 with effective date 02/05/2023. Accessed March 2023.

Appendix 1 – Covered Diagnosis Codes

ICD-10

ICD-10 Description

C64.1

Malignant neoplasm of right kidney, except renal pelvis

C64.2

Malignant neoplasm of left kidney, except renal pelvis

C64.9

Malignant neoplasm of unspecified kidney, except renal pelvis

C92.00

Myeloid leukemia not having achieved remission

C92.02

Myeloid leukemia in relapse

C92.50

Acute myelomonocytic leukemia not having achieved remission

C92.52

Acute myelomonocytic leukemia in relapse

C92.60

Acute myeloid leukemia with 11q23-abnormality not having achieved remission

C92.62

Acute myeloid leukemia with 11q23-abnormality in relapse

C92.A0

Acute myeloid leukemia with multilineage dysplasia not having achieved remission

C92.A2

Acute myeloid leukemia with multilineage dysplasia in relapse

C93.00

Acute monoblastic/monocytic leukemia not having achieved remission

C93.02

Acute monoblastic/monocytic leukemia in relapse

C93.10

Chronic myelomonocytic leukemia, not having achieved remission

D46.0

Refractory anemia without ring sideroblasts, so stated

D46.1

Refractory anemia with ring sideroblasts

D46.20

Refractory anemia with excess of blasts, unspecified

D46.21

Refractory anemia with excess of blasts 1

D46.4

Refractory anemia, unspecified

D46.9

Myelodysplastic syndrome, unspecified

D46.A

Refractory cytopenia with multilineage dysplasia

D46.B

Refractory cytopenia with multilineage dysplasia and ring sideroblasts

D46.Z

Other myelodysplastic syndrome

D61.81

Pancytopenia

D70.0

Congenital agranulocytosis

D70.1

Agranulocytosis secondary to cancer chemotherapy

D70.2

Other drug-induced agranulocytosis

D70.4

Cyclic neutropenia

D70.9

Neutropenia, unspecified

T45.1X5A

Adverse effect of antineoplastic and immunosuppressive drugs initial encounter

T45.1X5D

Adverse effect of antineoplastic and immunosuppressive drugs subsequent encounter

T45.1X5S

Adverse effect of antineoplastic and immunosuppressive drugs sequela

T66.XXXA

Radiation sickness, unspecified, initial encounter

T66.XXXD

Radiation sickness, unspecified, subsequent encounter

T66.XXXS

Radiation sickness, unspecified, sequela

W88.1

Exposure to radioactive isotopes

W88.8

Exposure to other ionizing radiation

Z41.8

Encounter for other procedures for purposes other than remedying health state

Z48.290

Encounter for aftercare following bone marrow transplant

Z51.11

Encounter for antineoplastic chemotherapy

Z51.12

Encounter for antineoplastic immunotherapy

Z51.89

Encounter for other specified aftercare

Z52.001

Unspecified donor, stem cells

Z52.011

Autologous donor, stem cells

Z52.091

Other blood donor, stem cells

Z76.89

Persons encountering health services in other specified circumstances

Z94.81

Bone marrow transplant status

Z94.84

Stem cells transplant status

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/Medicare-Coverage-Database/search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA):

Jurisdiction(s): J,M

NCD/LCD Document (s): A56748

https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=a56748&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP   

Jurisdiction(s):  N (9)

NCD/LCD Document (s): A57789

https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=a57789&areaId=all&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP   

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction

Applicable State/US Territory

Contractor

E (1)

CA, HI, NV, AS, GU, CNMI

Noridian Healthcare Solutions, LLC

F (2 & 3)

AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ

Noridian Healthcare Solutions, LLC

5

KS, NE, IA, MO

Wisconsin Physicians Service Insurance Corp (WPS)

6

MN, WI, IL

National Government Services, Inc. (NGS)

H (4 & 7)

LA, AR, MS, TX, OK, CO, NM

Novitas Solutions, Inc.

8

MI, IN

Wisconsin Physicians Service Insurance Corp (WPS)

N (9)

FL, PR, VI

First Coast Service Options, Inc.

J (10)

TN, GA, AL

Palmetto GBA, LLC

M (11)

NC, SC, WV, VA (excluding below)

Palmetto GBA, LLC

L (12)

DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)

Novitas Solutions, Inc.

K (13 & 14)

NY, CT, MA, RI, VT, ME, NH

National Government Services, Inc. (NGS)

15

KY, OH

CGS Administrators, LLC

 

 

 

FILGRASTIM (Neupogen®, Nivestym™, Zarxio™, Releuko® and Granix®) Prior Auth Criteria
Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2023, Magellan Rx Management

White MRx.PNG